Galmed Pharmaceuticals
GLMD
11 hedge funds and large institutions have $85.9K invested in Galmed Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
21% more capital invested
Capital invested by funds: $71.2K → $85.9K (+$14.7K)
0.02% more ownership
Funds ownership: 0.28% → 0.3% (+0.02%)
15% less funds holding
Funds holding: 13 → 11 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47K |
| 2 |
HF
HRT Financial
New York
|
+$26.2K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$344 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$30 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$39.3K |
| 2 |
Jane Street
New York
|
-$8.06K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.58K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$593 |
GLMD Hedge Fund Activity: Q2 2026 in Review
11 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2026, worth a combined $85.9K — up 21% from $71.2K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, adding an estimated $47K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $39.3K sold.
- 11 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2026, down from 13 in Q1 2026.
- Funds reported $85.9K of Galmed Pharmaceuticals stock for Q2 2026, up 21% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2026 was Citadel Advisors, an estimated $47K added.
- The largest Galmed Pharmaceuticals seller in Q2 2026 was Two Sigma Investments, an estimated $39.3K sold.
Based on aggregated 13F filings for Q2 2026.